Keywords: Novartis, Jetrea, Vitreomacular traction, VMT, Ilaris, Gouty arthritis, EMA, CHMP, ThromboGenics, Takeover target

Positive opinions for Novartis' Jetrea and Ilaris from EMA advisory panel

Article | 21 January 2013

Print This

Among a number of positive recommendations last Friday from the European Medicines Agency’s Committee for Medicinal Products for ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in